This page shows the latest montelukast news and features for those working in and with pharma, biotech and healthcare.
Earlier cases have involved Novartis' cancer drug Glivec (imatinib), Roche 's Pegasys (peginterferon alfa-2a) for hepatitis, Merck &Co's asthma treatment Singulair (montelukast), Gilead's HIV drug Viread (tenofovir) and
Merck's third-quarter results were hit as expected by the lingering effect of patent expiries on key products such as cancer drug Temodar (temozolomide) and Singulair (montelukast) for asthma, as
sales of asthma drug Singulair (montelukast) on generic competition, as well as a 14 per cent drop in net income to $781m.
This year has already seen IP setbacks in India for Novartis' leukaemia drug Glivec (imatinib), Merck &Co's Januvia (sitagliptin) diabetes franchise and Singulair (montelukast), Roche's Pegasys (peginterferon alfa-2a),
montelukast), Maxalt (rizatriptan) for migraines, blood pressure treatment Cozaar (losartan) and antihistamine Clarinex (desloratadine).
regarding Roche's Pegasys (peginterferon alfa-2a), Merck &Co's Singulair (montelukast), Gilead Sciences' Viread (tenofovir), Pfizer's Sutent (sunitinib) and Bayer's Nexavar (sorafenib tosylate).
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...